Granules India Limited — PPTs, 06-11-2024: Investor Presentation

Granules India reported its Q2 FY25 financial results, highlighting strong gross margins driven by formulation sales, while facing challenges in the API/PFI segment due to price erosion and high customer inventory. The company voluntarily paused production at its Gagillapur facility following a US FDA inspection but resumed operations in a staggered manner. Healthy cash flow from operations was noted, alongside new product approvals and launches, including Pantoprazole in the USA.